AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis.

Trial Profile

AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2014

At a glance

  • Drugs Fenofibrate (Primary) ; Atorvastatin
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms AFRICA
  • Most Recent Events

    • 16 Jun 2011 Additional trial investigator identified as reported by ClinicalTrials.gov.
    • 16 Jun 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 16 Jun 2011 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top